SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Abstract collage of Statue of Liberty, temple and money
China
Lilly Pumps $3B Into China To Boost Supply of Weight Loss Pill
Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China.
March 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of a yellow envelope on a blue background with a read warning symbol
GLP-1
Novo Hit With FDA Warning Letter for Unreported Ozempic Safety Signals
Among the unreported adverse events potentially linked to Ozempic are two deaths and one case of “completed suicide,” according to an FDA inspection report.
March 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Duchenne muscular dystrophy
Capricor Shares Rise as FDA Sets August Decision Date for Rejected Duchenne Therapy
Capricor Therapeutics’ deramiocel was rejected in July 2025, potentially caught between Nicole Verdun, a former top biologics regulator at the FDA, and outgoing Vinay Prasad, director of the Center for Biologics Evaluation and Research.
March 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Capitol Hill COVID-19 blood testing, abstract virus testing during pandemic concept, State Building Washington DC, USA, 3d illustration
Opinion
Rare Disease Patients Can’t Wait for Regulatory Process
The U.S. Senate has a plan to improve drug development for rare disease patients. The exit of controversial CBER chief Vinay Prasad will help clear the path.
March 11, 2026
 · 
5 min read
 · 
Joshua R. Mansbach
Podcast
Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections, and a Spate of Obesity Data
Rare disease biotech stocks pop on the news that Vinay Prasad, the FDA’s chief biologics regulator, will depart the FDA at the end of April; Sen. Ron Johnson launches an investigation into recent rare disease drug rejections; and Roche and Zealand’s amylin analog fails to match investor expectations—and Eli Lilly’s rival candidate—in a mid-stage trial.
March 11, 2026
 · 
1 min read
 · 
Heather McKenzie
Confrontation and opposite opinions concept. Business people hands pulling rope in opposite directions in office showing power and leadership vector illustration
Mergers & acquisitions
Pharma Is Ravenous for M&A Action but Late-Stage Supply Dwindles
Whether happening in public or private, biopharma M&A is fiercer than ever. Experts point to patent pressures, herd mentality and a declining stock of available biotechs with mature assets.
March 11, 2026
 · 
5 min read
 · 
Annalee Armstrong
External view of the U.S. Capitol Building
Rare diseases
Senator Ron Johnson Launches Investigation Into FDA Rare Disease Rejections
The senator, who has long advocated for expanding access to experimental therapies, reportedly called the FDA’s request for a sham surgery–controlled Phase 3 trial for uniQure’s Huntington’s disease gene therapy “bureaucratic idiocy.”
March 10, 2026
 · 
3 min read
 · 
Heather McKenzie
FDA signage at its headquarters in Maryland
Manufacturing
FDA Sets Scope for Attempt To Reduce Manufacturing-Related Approval Rejections
Industry and FDA representatives have reached a general agreement on planned pre-submission facility meetings but have expressed different views about the specifics.
March 10, 2026
 · 
2 min read
 · 
Nick Paul Taylor
BioNTech CEO Ugur Sahin and Chief MEdical Officer Özlem Türeci.
C-suite
BioNTech Founders To Leave Famed mRNA Biotech for New Venture
The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.
March 10, 2026
 · 
2 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS